Opening New Frontiers By Advancing The Promise of PI Signaling Pathways

David McElligott, Ph.D.

Select a team to find out more

David McElligott, Ph.D.

David McElligott, Ph.D.

Chief Scientific Officer

Dr. David McElligott joined Petra in 2017 after serving for more than half a decade as Chief Scientific Officer at Accelerator Corp.

As the founding Chief Scientific Officer at Groove Biopharma, a microRNA therapeutics company, David led the spin out of the technology from Nanogen (now part of ELITech Group).  Prior to founding Groove Biopharma in 2008, he served as Senior Director of Biological Sciences at ICOS Corp. where he led numerous pre-clinical drug discovery projects in oncology, inflammation, and urology.  Several of those projects led to successful IND filings and clinical development programs.  Before joining ICOS in 1997, David held academic appointments in the Department of Immunology at The Scripps Research Institute and The Salk Institute for Biological Sciences.

David earned a Ph.D. and a B.S. in microbiology/immunology from the University of Iowa.  He serves on the advisory boards of the NYU Innovation Venture Fund and Rockefeller University’s Robertson Therapeutic Development Fund.